Article Sidebar
Published:
Mar 15, 2019Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of Shensong Yangxin on heart failure in preserved ejection fraction rat model
Abstract
Methods: HFpEF rat model was established using abdominal aorta coarctation method and randomly divided into a positive drug control group; SSYX at high, medium, and low dosage groups; and normal control group. After 8 weeks oral treatment of SSYX, echocardiography and cardiac catheterization were used to investigate the effects of SSYX on HFpEF rat cardiac functions, including mean heart rate (HR), left ventricle anterior and posterior wall thicknesses at end diastole (LVAWd + LVPWd), left ventricular internal diameter at end diastole (LVIDd), and left ventricle mass (LVM).
Results: SSYX markedly decreased heart weight and improved survival rate (p < 0.01) after 12 weeks of treatment. The expression of NT-proBNP decreased in a dose-dependent manner and was significantly lower in SSYX treatment groups (p < 0.01). Compared with normal control group, expression of CaMK II, PKA and RyR2 was significantly lower (p < 0.005), while expression level of SERCA2a significantly increased after 4 g/kg/day SSYX treatment (p < 0.01).
Conclusion: SSYX significantly attenuates HFpEF-induced cardiac dysfunction and increases survival rate, suggesting that SSYX may prevent HF via regulation of cytoplasmic Ca2+ handling. SSYX reduces plasma NT-proBNP levels, lending support for its therapeutic potential in HF management.
Keywords: Heart failure, Ejection fraction, ShensongYangxin
